 Fennec Pharmaceuticals Inc. FENC FRX.TO, a specialty pharmaceutical company focused on the development of PEDMARKTM a unique formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity from cisplatin in pediatric cancer patients, today announced the pricing of its underwritten public offering of 4,800,000 common shares at a public offering price of 6.25 per share. In addition, Fennec has granted the underwriters a 30-day option to purchase up to an additional 720,000 common shares. Fennec anticipates the total gross proceeds from the offering before deducting the underwriting discounts and offering expenses will be 30 million, excluding any exercise of the underwriters option to purchase additional shares. 